Amachiza e-GLP-1 afana ne-Ozempic kunye ne-Wegovy
- Uphando olutsha olunikezelwe kwi-American Heart Association Scientific Sessions lubonisa ukuba i-semaglutide, isithako esisebenzayo kwi-Ozempic kunye ne-Wegovy, ineempembelelo ezibalulekileyo kwimpilo yentliziyo.
- Ubungqina bubonise ukuba abaguli abanyangwa nge-GLP-1 benomngcipheko oncitshisiweyo wokuhlaselwa sisifo sentliziyo kunye ne-stroke.
- Iimpawu zokungaphumeleli kwentliziyo nazo ziphuculwe ngexesha lokunyanga nge-semaglutide.
I-Semaglutide, ichiza le-GLP-1 ekuqaleni lalimiselwe isifo seswekile kwaye emva koko ukutyeba kakhulu, kungekudala inokunyanga isifo sentliziyo.
Ngempelaveki, kwi-American Heart Association Scientific Sessions 2023, abaphandi babonisa ubungqina obubambekayo bokusebenza kwe-semaglutide (ithengiswa phantsi kwegama le-brand Wegovy kunye ne-Ozempic) ekukhuseleni ukuhlaselwa kwentliziyo kunye nokubetha.
Olunye uphando luye lwabonisa ukuba iyeza lingasetyenziselwa ukuphucula iimpawu kwizigulana ezinokusilela kwentliziyo, ngakumbi ukusilela kwentliziyo kunye neqhezu le-ejection eligciniweyo (HFpEF).
Kuthatyathwe kunye, ezi zifundo zimbini, ezathi kamva zapapashwa kwiijenali ezinkulu zonyango, zibonisa isithembiso se-semaglutide njengokhetho lonyango kwizigulana ezisengozini yeziganeko ezinkulu zentliziyo kunye nokungaphumeleli kwentliziyo.
Kuzo zombini ezi meko, uphando luxhaswe nguNovo Nordisk, umenzi we-Ozempic kunye ne-Wegovy.
Ngaba i-semaglutide inenzuzo ye-cardiovascular?
Uphononongo olunikezelwe kule mpelaveki kwaye lupapashwe ngaxeshanye kwiNew England Journal of Medicine luhlolisise iziphumo ezivela kwi-SELECT trial, i-multicenter, i-double-blind, i-randomized, i-placebo-controlled controlled trial eyenziwa nguNovo Nordisk ukufundisisa iziphumo ze-cardiovascular kwizigulane eziphathwa nge-semaglutide. ngokuchasene ne-placebo.
Uphando oluthiwe thaca kule mpelaveki lujonga amazinga okusweleka, uhlaselo lwentliziyo olungabulaliyo kunye nemivimbo engabulaliyo kwizigulana ezingenasifo seswekile. Ichiza liye laboniswa ngaphambili ukunciphisa ezi ziganeko kwizigulane ezinesifo sikashukela sohlobo lwe-2.
Olu lingo lelona likhulu kwakha lwenziwa yinkampani yaseDenmark exuba amayeza kwaye libandakanye abantu abangaphezu kwe-17 kumazwe angama-000.
Uphononongo lwenziwe phakathi kuka-Oktobha 2018 kunye no-Matshi 2021 kwaye lwahlala iminyaka emihlanu, kubandakanywa nexesha lokulandelela isigulane.
Ngethuba lovavanyo, isiqingatha sabathathi-nxaxheba bafumana i-semaglutide (i-dose ye-2,4 mg kanye ngeveki), ngelixa esinye isiqingatha safumana i-placebo. Izigulane kulingo zazineminyaka eyi-45 okanye ngaphezulu, zine-BMI ye-27 okanye ngaphezulu, kwaye zine-cardiovascular disease esele ikhona. Kwakufuneka bangabi nayo imbali yesifo seswekile.
Izigulane ezithatha i-semaglutide zazinomngcipheko weengxaki ezinzulu ze-cardiovascular ezincitshiswe kwibhodi yonke: ingozi yonke yesiganeko se-cardiovascular yehle nge-20%, umngcipheko wokuhlaselwa yintliziyo nge-28%, kunye nomngcipheko wokubetha nge-7%.
Kwakukho iingenelo ezongezelelweyo ngokunjalo. Iqela le-semaglutide lilahlekelwe yi-9,39% yesisindo somzimba wabo, xa kuthelekiswa ngaphantsi kwe-1% yeqela le-placebo. Baphinde babona ukuphuculwa koxinzelelo lwegazi, amanqanaba e-cholesterol kunye namanqanaba e-HbA1c.
I-Novo Nordisk ikhuphe ngaphambili idatha yesiseko kwi-SELECT iziphumo zolingo ngo-Agasti.
Ngaba i-semaglutide inceda ngokuhluleka kwentliziyo?
Uphando olupapashwe ngoNovemba 12 ngo Ukuhambaukupapashwa kwe-flagship ye-American Heart Association, yafunda unyango lwe-semaglutide ukuphucula iimpawu zokungaphumeleli kwentliziyo kunye neqhekeza eligciniweyo le-ejection, eyona ndlela ixhaphakileyo yokuhluleka kwentliziyo.
Abaphandi bajonge amanyathelo ahlukeneyo kwimimandla efana nomgangatho wobomi, ukulinganiselwa kwezentlalo, kunye nokunciphisa umzimba usebenzisa i-Kansas City Cardiomyopathy Questionnaire (KCCQ), enika amanqaku eempawu zokungaphumeleli kwentliziyo ngokusekelwe kwimiba yezinto.
I-52-iveki, i-randomized, i-double-blind-blind, isilingo esilawulwa yi-placebo sasiquka abathathi-nxaxheba be-529. Isiqingatha sabathathi-nxaxheba bafumana inaliti yeveki ye-2,4 mg ye-semaglutide, ngelixa esinye isiqingatha safumana i-placebo. Izigulana kwafuneka zibe nokutyeba kakhulu kunye nembali ebhaliweyo ye-HFpEF.
Abantu abaphathwa nge-semaglutide bafumana ukuphuculwa okuphawulekayo kwiimpawu zokungaphumeleli kwentliziyo, eziboniswe ngokuphucula amanqaku e-KCCQ, ukunciphisa okukhulu kwesisindo somzimba, kunye nokuphucula ukulinganiselwa komzimba kunye nomsebenzi wokuzivocavoca.
“Ngoku sikwinqanaba lokunyuka kwedatha esikhomba kwicala lokuba ukutyeba kakhulu ngunobangela wezi ngxaki. Ukuze silawule ngempumelelo ezi ngxaki, kufuneka sijongane nokukhuluphala, kufuneka sijolise ukutyeba, "uGqr Mikhail Kosiborod, i-cardiologist, i-vice-president wophando kwi-Saint Luke's Health System kunye nomlobi okhokelayo wokufunda. isifundo, uxelele i-Healthline.
Iziphumo zakhela kwizinto ezifunyenwe ngaphambili ezipapashwe ekuqaleni kwalo nyaka.
I-HFpEF ibhekisa kwiintlobo ezahlukeneyo zokungaphumeleli kwentliziyo apho intliziyo ilukhuni kakhulu ukuba izalise ngokufanelekileyo.
Nangona ukungaphumeleli kwentliziyo kunye nokutyeba ziimeko zempilo ezahlukeneyo, zihlala zisenzeka kunye. Uphononongo kwi JAMA Ekuqaleni kwalo nyaka, kwafunyaniswa ukuba abantu abatyebileyo okanye abatyebe kakhulu be-BMI babenomngcipheko ophezulu kakhulu we-HFpEF.
UGqr Lynne Warner Stevenson, uprofesa weyeza ze-cardiovascular eVanderbilt kunye nomlawuli wenkqubo yabo ye-cardiomyopathy, owayengahambelani nophando, utshele i-Healthline:
“Kuluvuthondaba lweliza eliye laphuhla ukuzama ukufumana indlela yokunciphisa izigulo kunye nokufa kwento endiyijonga njengomfanekiso weVenn wezifo, kukutyeba, isifo seswekile kunye nesifo sentliziyo. ukusilela ngeqhezu lokukhupha eligciniweyo.
Amachiza e-GLP-1 anceda ukunyanga isifo seswekile, ukutyeba kunye nesifo senhliziyo
"Ndicinga ukuba wonke umntu unemincili kwaye sonke besilindile, ngakumbi ulingo KHETHA, kwaye ndicinga ukuba ziindaba ezimnandi," utshilo uGqr. Sun Kim, unjingalwazi onxulumene neyeza kwi-endocrinology kwiYunivesithi yaseStanford, uxelele i-Healthline. Akazange athathe inxaxheba kuphando.
"Iingcali ze-Endocrinologists zinobudlelwane obuthile kule klasi yeziyobisi kuba zavunywa kuqala unyango lwesifo sikashukela sohlobo lwe-2 kunye nokulawula iswekile yegazi, kodwa zibonakaliswe ukuba zineenzuzo ezininzi ezongezelelweyo," wachaza.
Ababhali bohlelo olukhaphayo kwi NEJM ubhale wathi: “Sikwixesha elitsha lokunyanga ukutyeba kakhulu kunye nomngcipheko we-cardiometabolic ngoluhlu olukhulayo lwezinto onokukhetha kuzo. Ulingo lwe-SELECT lubonelela ngobungqina beziphumo eziphuculweyo zesifo senhliziyo kunye ne-GLP-1 receptor agonists ngokungabikho kweswekile.
Nangona kunjalo, baphinde baqaphela ukuba iindleko kunye nokufikeleleka kwe-semaglutide zihlala ziyimiqobo ebalulekileyo kubantu abaninzi.
I-Novo Nordisk ifake isicelo sokuhlaziya ileyibhile ye-Wegovy ukubandakanya isalathiso sokunciphisa iziganeko ezinkulu ezimbi zentliziyo. I-FDA inike uhlaziyo oluphambili lophononongo kwesi sicelo sechiza esitsha esongezelelweyo.
Inkampani ibonelele nge-Healthline ingxelo elandelayo evela kuDkt Michelle Skinner, i-PharmD, inkokeli yendawo ye-cardiorenal therapy, imicimbi yezonyango eNovo Nordisk:
"Iziphumo ezipheleleyo ze-KHETHA ezinikezelwe kwi-AHA ziphawula inguqu kwisayensi yokutyeba. Sijonge phambili ekusebenzisaneni nabalawuli kumanyathelo alandelayo okubonelela ngolu khetho kubantu abatyebileyo okanye abatyebileyo kunye nababoneleli bezempilo abasebenzisana nabo ekunyamekeleni kwabo.
Okubalulekileyo
Ubungqina obuvelayo bubonisa ukuba i-semaglutide ingaba neenzuzo ezibalulekileyo kwimpilo ye-cardiovascular and heart failure.
Ngokutsho kwedatha evela kulingo lwe-KHETHA lweNovo Nordisk, izigulane eziphathwa nge-semaglutide zine-20% yokunciphisa umngcipheko weziganeko ezimbi kakhulu ze-cardiovascular xa kuthelekiswa ne-placebo.
Ulingo olwahlukileyo lukwabonise ukuba ichiza lalisebenza kakuhle ekunyangeni iimpawu zokungaphumeleli kwentliziyo ngeqhekeza eligciniweyo le-ejection.
FUNDA OKUNGAKUMBI FUNDA OKUNGAKUMBI FUNDA OKUNGAKUMBI FUNDA OKUNGAKUMBI FUNDA OKUNGAKUMBI